Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue.
Stjernschantz
J
J
Glaucoma Research Laboratories, Pharmacia Ophthalmics, Uppsala, Sweden.
Selén
G
G
Sjöquist
B
B
Resul
B
B
D000287:Administration, Topical; D000818:Animals; D001082:Aqueous Humor / Q000187:drug effects / Q000502:physiology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002415:Cats; D002417:Cattle; D003315:Cornea / Q000098:blood supply; D003331:Coronary Vessels / Q000502:physiology*; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology; D015237:Dinoprost / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects / Q000502:physiology; D066298:In Vitro Techniques; D007498:Iris / Q000098:blood supply / Q000187:drug effects; D000077338:Latanoprost; D008252:Macaca fascicularis; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D009928:Organ Specificity; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011817:Rabbits; D012039:Regional Blood Flow / Q000187:drug effects; D013552:Swine; D014649:Vas Deferens / Q000187:drug effects / Q000502:physiology
D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D015237:Dinoprost